Highlight Therapeutics closes a €15 million funding round led by Buenavista

by Highlight Therapeutics

9 months ago
Highlight Therapeutics, Columbus Venture Partners, Buenavista Equity Partners

Highlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...

Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT gene writing platform and preclinical validation of CAR-T therapies

by Integra Therapeutics

9 months ago
Integra Therapeutics, EIC Fund, CDTI Innvierte, AdBio Partners, Columbus Venture Partners, Invivo Partners, Takeda Ventures

The funds come from new investors like the EIC Fund and CDTI Innvierte, as well as from existing investors AdBio Partners, Columbus Venture Partners, Invivo Partners and Takeda Ventures, which continu...

deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection

by Deepull

1 year ago
deepull, Columbus Venture Partners, Panakès Partners, Mérieux Equity Partners, Asabys Partners, Innvierte-CDTI, Axis-ICO, Aliath Bioventures, Kurma Partners

Proceeds from the Series C will be deployed to finalize clinical validation and expedite the regulatory approval process of deepull’s UllCORE diagnostic system, which received Breakthrough Device De...

ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by ARTHEx Biotech

2 years ago
Myotonic Dystrophy Type 1 (DM1)., ATX-01, ArthemiRTM, MBNL proteins, ARTHEx Biotech, Columbus Venture Partners

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs backed by Columbus Venture Partners, has announced that the ...

MONDRAGON y Bexen Medical invierten en Cocoon Bioscience

by Cocoon Bioscience

3 years ago
Bexen Medical, Columbus Venture Partners, Cleon Capital, North South Ventures, Sangha Capital, MONDRAGON

Cocoon Bioscience ha levantado €2 millones en una ronda de inversión liderada por MONDRAGON, Bexen Medical, Columbus Venture Partners y Cleon Capital, y que ha incluido a su vez a Viscofan, la esta...

Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

5 years ago
Mirum Pharmaceuticals, Vivet Therapeutics, Columbus Venture Partners, Ysios Capital

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...

Almirall and Tyris Therapeutics develop next generation gene therapies

by Almirall

5 years ago
rare genetic dermatology diseases, Almirall, Tyris Therapeutics, Columbus Venture Partners

Almirall, a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company founded by Columbus Venture Partners, have announced a strategic ...

Algenex cierra nueva ronda de financiación por 7,4 millones para afrontar sus nuevos proyectos en salud humana

by ALGENEX

6 years ago
CrisBio, Vita Advisory, Cleon Capital, MasterLux, salud, Algenex, Columbus Life Science Fund II, Columbus Venture Partners

La compañía biotecnológica Algenex ha cerrado una ronda de financiación privada por valor de 7,4 millones de euros liderada por MasterLux, inversor asesorado por Cleon Capital y Vita Advisory. Est...

Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

7 years ago
Ysios Capital, Aura Biosciences, Lundbeckfonden, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

by Ysios Capital

Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financ...